Daily Newsletter

30 August 2023

Daily Newsletter

30 August 2023

FDA approves ICU Medical’s Plum Duo pump with LifeShield software

The company aims to distribute the Plum Duo pump and LifeShield software to US customers next year.

RanjithKumar Dharma August 30 2023

The US Food and Drug Administration (FDA) has granted 510(k) clearance for ICU Medical’s Plum Duo infusion pump with LifeShield infusion safety software.

Part of the company’s infusion device portfolio, the Plum Duo pump is based on the accurate delivery of Plum 360’s cassette technology.

Plum Duo comes with a large colour touchscreen with an advanced user interface and two channels that can deliver up to four compatible IV medications.

Designed as a unified cloud-based software suite, the LifeShield infusion safety software features advanced new tools to comprehensively manage the drug library.

It promotes collaboration by improving clinicians' capacity to readily access, process, and rapidly exchange information throughout an entire enterprise or health system.

The company plans to supply the Plum Duo pump and LifeShield software to US customers next year.

ICU Medical Infusion Systems general manager and corporate vice-president Dan Woolson said: “Receiving FDA clearance for the Plum Duo pump and LifeShield software is the first step in realising ICU Medical's long-term vision of bringing customers best-of-breed devices with a shared platform and user experience.

“We are proud of this milestone and look forward to bringing our next-generation Medfusion and CADD products to the LifeShield platform, creating the most complete, precise, and technologically advanced infusion systems in the industry for our customers and their patients.”

The company’s infusion system portfolio also includes Medfusion 4000 syringe pumps, CADD-Solispain management pumps, and CADD-Solis VIPambulatory pumps, as well as Plum 360 large volume pumps.

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close